A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer
The purpose of this study is to determine the disease control rate at trial closure and after the first stage of the study in patients with relapsed or refractory SCLC and measurable disease treated with gefitinib
Small Cell Lung Cancer
DRUG: Gefitinib
To determine the disease control rate in these patients
To determine the objective response rate at trail closure in these patients|To determine the time to progression-or-death in these patients|To determine overall survival in these patients
The purpose of this study is to determine the disease control rate at trial closure and after the first stage of the study in patients with relapsed or refractory SCLC and measurable disease treated with gefitinib